vs

Side-by-side financial comparison of C.H. Robinson (CHRW) and Labcorp (LH). Click either name above to swap in a different company.

C.H. Robinson is the larger business by last-quarter revenue ($3.9B vs $3.5B, roughly 1.1× Labcorp). Labcorp runs the higher net margin — 4.7% vs 3.5%, a 1.2% gap on every dollar of revenue. On growth, Labcorp posted the faster year-over-year revenue change (5.6% vs -6.5%). Labcorp produced more free cash flow last quarter ($490.3M vs $302.4M). Over the past eight quarters, Labcorp's revenue compounded faster (5.2% CAGR vs -5.8%).

C.H. Robinson Worldwide, Inc. is an American transportation company that includes third-party logistics (3PL). The company offers freight transportation, transportation management, brokerage and warehousing. It offers truckload, less than truckload, air freight, intermodal, and ocean transportation.

Labcorp is a leading global life sciences and diagnostic testing firm that offers comprehensive clinical laboratory services, drug development support, and medical testing solutions for healthcare providers, pharmaceutical companies, and individual patients. It uses advanced scientific expertise and innovative technologies to deliver accurate, actionable health insights that support clinical decisions, accelerate new treatment development, and improve patient health outcomes globally.

CHRW vs LH — Head-to-Head

Bigger by revenue
CHRW
CHRW
1.1× larger
CHRW
$3.9B
$3.5B
LH
Growing faster (revenue YoY)
LH
LH
+12.1% gap
LH
5.6%
-6.5%
CHRW
Higher net margin
LH
LH
1.2% more per $
LH
4.7%
3.5%
CHRW
More free cash flow
LH
LH
$187.9M more FCF
LH
$490.3M
$302.4M
CHRW
Faster 2-yr revenue CAGR
LH
LH
Annualised
LH
5.2%
-5.8%
CHRW

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CHRW
CHRW
LH
LH
Revenue
$3.9B
$3.5B
Net Profit
$136.3M
$164.7M
Gross Margin
28.2%
Operating Margin
4.6%
7.6%
Net Margin
3.5%
4.7%
Revenue YoY
-6.5%
5.6%
Net Profit YoY
-8.7%
14.9%
EPS (diluted)
$1.12
$1.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHRW
CHRW
LH
LH
Q4 25
$3.9B
$3.5B
Q3 25
$4.1B
$3.6B
Q2 25
$4.1B
$3.5B
Q1 25
$4.0B
$3.3B
Q4 24
$4.2B
$3.3B
Q3 24
$4.6B
$3.3B
Q2 24
$4.5B
$3.2B
Q1 24
$4.4B
$3.2B
Net Profit
CHRW
CHRW
LH
LH
Q4 25
$136.3M
$164.7M
Q3 25
$163.0M
$261.1M
Q2 25
$152.5M
$237.9M
Q1 25
$135.3M
$212.8M
Q4 24
$149.3M
$143.4M
Q3 24
$97.2M
$169.3M
Q2 24
$126.3M
$205.3M
Q1 24
$92.9M
$228.0M
Gross Margin
CHRW
CHRW
LH
LH
Q4 25
28.2%
Q3 25
28.8%
Q2 25
29.7%
Q1 25
28.3%
Q4 24
26.9%
Q3 24
27.6%
Q2 24
28.8%
Q1 24
28.2%
Operating Margin
CHRW
CHRW
LH
LH
Q4 25
4.6%
7.6%
Q3 25
5.3%
11.1%
Q2 25
5.2%
11.2%
Q1 25
4.4%
9.7%
Q4 24
4.4%
6.5%
Q3 24
3.9%
7.7%
Q2 24
4.0%
9.2%
Q1 24
2.9%
10.1%
Net Margin
CHRW
CHRW
LH
LH
Q4 25
3.5%
4.7%
Q3 25
3.9%
7.3%
Q2 25
3.7%
6.7%
Q1 25
3.3%
6.4%
Q4 24
3.6%
4.3%
Q3 24
2.1%
5.2%
Q2 24
2.8%
6.4%
Q1 24
2.1%
7.2%
EPS (diluted)
CHRW
CHRW
LH
LH
Q4 25
$1.12
$1.98
Q3 25
$1.34
$3.12
Q2 25
$1.26
$2.84
Q1 25
$1.11
$2.52
Q4 24
$1.23
$1.72
Q3 24
$0.80
$2.00
Q2 24
$1.05
$2.43
Q1 24
$0.78
$2.69

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHRW
CHRW
LH
LH
Cash + ST InvestmentsLiquidity on hand
$160.9M
$532.3M
Total DebtLower is stronger
$1.1B
Stockholders' EquityBook value
$1.8B
$8.6B
Total Assets
$5.1B
$18.4B
Debt / EquityLower = less leverage
0.59×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHRW
CHRW
LH
LH
Q4 25
$160.9M
$532.3M
Q3 25
$136.8M
$598.1M
Q2 25
$156.0M
$647.3M
Q1 25
$129.9M
$369.4M
Q4 24
$145.8M
$1.5B
Q3 24
$131.7M
$1.5B
Q2 24
$113.2M
$265.1M
Q1 24
$121.8M
$99.3M
Total Debt
CHRW
CHRW
LH
LH
Q4 25
$1.1B
Q3 25
$1.2B
Q2 25
$1.4B
Q1 25
$1.4B
Q4 24
$1.4B
Q3 24
$1.6B
Q2 24
$1.6B
Q1 24
$1.7B
Stockholders' Equity
CHRW
CHRW
LH
LH
Q4 25
$1.8B
$8.6B
Q3 25
$1.9B
$8.7B
Q2 25
$1.8B
$8.5B
Q1 25
$1.7B
$8.3B
Q4 24
$1.7B
$8.1B
Q3 24
$1.6B
$8.2B
Q2 24
$1.5B
$8.0B
Q1 24
$1.4B
$8.0B
Total Assets
CHRW
CHRW
LH
LH
Q4 25
$5.1B
$18.4B
Q3 25
$5.2B
$18.3B
Q2 25
$5.3B
$18.1B
Q1 25
$5.2B
$17.6B
Q4 24
$5.3B
$18.4B
Q3 24
$5.6B
$18.6B
Q2 24
$5.5B
$16.7B
Q1 24
$5.5B
$16.5B
Debt / Equity
CHRW
CHRW
LH
LH
Q4 25
0.59×
Q3 25
0.64×
Q2 25
0.76×
Q1 25
0.80×
Q4 24
0.80×
Q3 24
0.95×
Q2 24
1.07×
Q1 24
1.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHRW
CHRW
LH
LH
Operating Cash FlowLast quarter
$305.4M
$614.2M
Free Cash FlowOCF − Capex
$302.4M
$490.3M
FCF MarginFCF / Revenue
7.7%
13.9%
Capex IntensityCapex / Revenue
0.1%
3.5%
Cash ConversionOCF / Net Profit
2.24×
3.73×
TTM Free Cash FlowTrailing 4 quarters
$894.9M
$1.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHRW
CHRW
LH
LH
Q4 25
$305.4M
$614.2M
Q3 25
$275.4M
$387.2M
Q2 25
$227.1M
$620.6M
Q1 25
$106.5M
$18.5M
Q4 24
$267.9M
$777.2M
Q3 24
$108.1M
$277.3M
Q2 24
$166.4M
$561.1M
Q1 24
$-33.3M
$-29.8M
Free Cash Flow
CHRW
CHRW
LH
LH
Q4 25
$302.4M
$490.3M
Q3 25
$269.5M
$280.5M
Q2 25
$219.8M
$542.7M
Q1 25
$103.2M
$-107.5M
Q4 24
$265.3M
$665.1M
Q3 24
$103.3M
$161.5M
Q2 24
$159.8M
$432.9M
Q1 24
$-41.9M
$-163.6M
FCF Margin
CHRW
CHRW
LH
LH
Q4 25
7.7%
13.9%
Q3 25
6.5%
7.9%
Q2 25
5.3%
15.4%
Q1 25
2.5%
-3.2%
Q4 24
6.3%
20.0%
Q3 24
2.2%
4.9%
Q2 24
3.6%
13.4%
Q1 24
-1.0%
-5.2%
Capex Intensity
CHRW
CHRW
LH
LH
Q4 25
0.1%
3.5%
Q3 25
0.1%
3.0%
Q2 25
0.2%
2.2%
Q1 25
0.1%
3.8%
Q4 24
0.1%
3.4%
Q3 24
0.1%
3.5%
Q2 24
0.1%
4.0%
Q1 24
0.2%
4.2%
Cash Conversion
CHRW
CHRW
LH
LH
Q4 25
2.24×
3.73×
Q3 25
1.69×
1.48×
Q2 25
1.49×
2.61×
Q1 25
0.79×
0.09×
Q4 24
1.79×
5.42×
Q3 24
1.11×
1.64×
Q2 24
1.32×
2.73×
Q1 24
-0.36×
-0.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHRW
CHRW

North American Service Transportation NAST$2.8B72%
Global Forwarding$731.0M19%
Sourcing$340.9M9%

LH
LH

Diagnostics$2.7B78%
Biopharma Laboratory Services$793.0M23%

Related Comparisons